Production of leukemia inhibitory factor mRNA and protein by malignant and immortalized bone cells
Open Access
- 1 May 1993
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 8 (5) , 617-624
- https://doi.org/10.1002/jbmr.5650080513
Abstract
Leukemia inhibitory factor (LIF) is a recently characterized glycoprotein with complex biologic activities on bone cells. We tested various rodent and human immortalized and malignant bone cell lines and primary osteoblast-enriched cell cultures from fetal rat calvarial digests for expression of LIF mRNA and LIF protein. Both human and rodent immortalized and malignant cells expressed a single 4.4 kb mRNA transcript that hybridized to a human LIF cDNA probe in Northern blots. LIF mRNA was undetectable in unstimulated rodent osteoblast-like cells lines MC3T3-E1 and Pyla. However, treatment with LPS (10 μg/ml), TGF-β (1 ng/ml), TNF-α (100 ng/ml) or inhibitors of protein synthesis (cycloheximide, emetine, puromycin, and anisomycin) induced the expression of LIF message in these cells. In contrast, primary osteoblast-enriched cells did not express LIF mRNA in Northern blot assays either constitutively or after treatment with TNF-α or cycloheximide. The human osteosarcoma cells lines U-2 OS and Saos-2 constitutively expressed LIF mRNA and did not respond to LPS treatment. However, phorbol myristate acetate (PMA), an activator of protein kinase C, was a potent stimulator of LIF message in Saos-2 but not U-2 OS cells. The effects of PMA (0.5 ng/ml) on LIF mRNA in Saos-2 cells were detectable at 1 h and maximal at 6 h. TNF-α (100 ng/ml) and inhibitors of protein synthesis also increased LIF mRNA in both Saos-2 and U-2 OS cells. LIF protein was also detected constitutively in the conditioned medium from both Saos and U-2 OS cells. In addition, TNF (100 ng/ml) stimulated the release of LIF protein from both these cells and PMA (2.5 ng/ml) stimulated LIF protein in Saos-2 cells. These results show that several different human malignant and rodent immortalized clonal bone cell lines can express and regulate steady-state LIF mRNA levels and produce LIF protein but that primary cultures of fetal rat osteoblastic cells do not express this cytokine. Hence, LIF may regulate malignant osteogenic cell growth and function in bone but may not be an important regulator of normal bone metabolism.Keywords
Funding Information
- National Institutes of Health (AR31263, AR38933)
- Department of Veterans Affairs Research Service
This publication has 32 references indexed in Scilit:
- Osteoblasts display receptors for and responses to leukemia‐inhibitory factorJournal of Cellular Physiology, 1990
- Leukemia inhibitory factor (LIF) inhibits basal bone resorption in fetal rat long bone culturesCytokine, 1990
- The Cholinergic Neuronal Differentiation Factor from Heart Cells Is Identical to Leukemia Inhibitory FactorScience, 1989
- Identification of an AUUUA-Specific Messenger RNA Binding ProteinScience, 1989
- A differentiation-inducing factor produced by the osteoblastic cell line MC3T3-E1 stimulates bone resorption by promoting osteoclast formationJournal of Bone and Mineral Research, 1988
- Leukaemia inhibitory factor is identical to the myeloid growth factor human interleukin for DA cellsNature, 1988
- Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cellsNature, 1988
- In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria.The Journal of cell biology, 1983
- What Marrow Does to BoneNew England Journal of Medicine, 1981
- Number and evolutionary conservation of α- and β-tubulin and cytoplasmic β- and γ-actin genes using specific cloned cDNA probesCell, 1980